Expansion Opportunities Cleerly is actively expanding access to cardiovascular research through mobile CT collaborations in multiple Southern states and partnerships with imaging providers, which presents a clear entry point for regional hospital systems, clinics, and research centers to adopt AI-driven imaging solutions and participate in TRANSFORM trials.

AI Diagnostics Growth With substantial Series C funding and a focus on AI-enabled quantitative coronary CT analysis, Cleerly offers a compelling value proposition to health systems seeking to modernize CAD diagnosis, enabling upsell to larger hospital networks, imaging centers, and enterprise AI platforms.

Risk Stratification The collaboration potential with Allelica for polygenic cardiovascular risk scoring creates cross-sell opportunities to primary care networks, specialty clinics, and payer programs that aim to integrate genetic risk with Cleerly’s imaging analytics for personalized prevention strategies.

Clinical Evidence Presentations and multicenter studies involving thousands of patients at ESC Congress and SCCT highlight Cleerly’s credibility; leverage these findings to engage academic medical centers, procurement committees, and research-oriented health systems seeking evidence-backed imaging tools.

SaaS and Services Cleerly’s tech stack and cloud-based imaging analytics position it to offer scalable software as a service, with potential for managed services, data workflow integrations, and customized reporting, appealing to large radiology groups and health information exchanges seeking streamlined AI-enabled diagnosis workflows.